Literature DB >> 17109182

Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.

Kenneth E Ugen1, Susan B Nyland.   

Abstract

The recreational use of legal and illegal drugs has significant effects on immune responses and can potentially modulate susceptibility to infection by a number of pathogens. A number of agents including cannabinoids (marijuana), cocaine opiates, amphetamines, nicotine and alcohol were demonstrated to have potentially adverse effects on the susceptibility to infections, mediated most likely, by adverse effects on immunity. As such, these drugs of abuse could have significant and potentially adverse effects on the vaccination efficacy of a number of vaccines currently on the market and on potential experimental vaccines currently in the pipeline. This review will present an overview on how drugs of abuse potentially impacts immune responses and vaccination efficacy. The emphasis of this review will be the effects of opiate abuse, as exemplified by injecting/intravenous drug users (IDU), on HIV/AIDS and its potential impact on vaccine efficacy trials against this devastating infection/syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109182     DOI: 10.1007/s00281-006-0045-0

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  63 in total

1.  Does human T-cell lymphotropic virus type I and human immunodeficiency virus type 1 coinfection accelerate acquired immunodeficiency syndrome? The jury is still out.

Authors:  F R Cleghorn; W A Blattner
Journal:  Arch Intern Med       Date:  1992-07

Review 2.  Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action.

Authors:  R D Mellon; B M Bayer
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

Review 3.  Opioids, receptors, and immunity.

Authors:  M W Adler; E B Geller; T J Rogers; E E Henderson; T K Eisenstein
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

Review 4.  Opiate inhibition of chemokine-induced chemotaxis.

Authors:  M C Grimm; A Ben-Baruch; D D Taub; O M Howard; J M Wang; J J Oppenheim
Journal:  Ann N Y Acad Sci       Date:  1998-05-01       Impact factor: 5.691

Review 5.  Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system.

Authors:  H W Haverkos
Journal:  J Subst Abuse Treat       Date:  1991

6.  Clinical spectrum of HTLV-I in south Florida.

Authors:  W J Harrington; A Ucar; P Gill; S Snodgrass; W Sheremata; L Cabral; M Rabin; G E Byrne; J Berger; W Voight
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-15

Review 7.  In vivo effects of cocaine on immune cell function.

Authors:  T Pellegrino; B M Bayer
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

8.  Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells.

Authors:  P K Peterson; G Gekker; S Hu; W R Anderson; F Kravitz; P S Portoghese; H H Balfour; C C Chao
Journal:  J Neuroimmunol       Date:  1994-03       Impact factor: 3.478

9.  Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers.

Authors:  M P Yeager; T A Colacchio; C T Yu; L Hildebrandt; A L Howell; J Weiss; P M Guyre
Journal:  Anesthesiology       Date:  1995-09       Impact factor: 7.892

10.  Effect of morphine on resistance to infection.

Authors:  E Tubaro; G Borelli; C Croce; G Cavallo; C Santiangeli
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

View more
  6 in total

Review 1.  Immunology as it pertains to drugs of abuse, AIDS and the neuroimmune axis: mediators and traffic.

Authors:  Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2010-10-19       Impact factor: 4.147

2.  Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users.

Authors:  Costin Tomescu; Fuh-Mei Duh; Michael A Lanier; Angela Kapalko; Karam C Mounzer; Maureen P Martin; Mary Carrington; David S Metzger; Luis J Montaner
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

3.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

4.  Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses.

Authors:  Sandy Pelletier; Christian Drouin; Nathalie Bédard; Salim I Khakoo; Julie Bruneau; Naglaa H Shoukry
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

5.  Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.

Authors:  Arame Thiam-Diouf; Barbara Metch; Cameron Sharpe; Robel Mulugeta; Michele Peake Andrasik
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

6.  Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.

Authors:  Erinn S Raborn; Guy A Cabral
Journal:  J Pharmacol Exp Ther       Date:  2010-01-20       Impact factor: 4.030

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.